Results 31 to 40 of about 22,909 (180)

Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease

open access: yesFrontiers in Neurology, 2023
The most frequently utilized biomarkers to support a pre-mortem clinical diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD) include concentrations of the 14-3-3 and total tau (T-tau) proteins, as well as the application of protein amplification ...
Matteo Senesi   +18 more
doaj   +1 more source

Clinical Features of Rapidly Progressive Alzheimer's Disease [PDF]

open access: yes, 2010
Objective: To characterize clinical features, CSF biomarkers and genetic polymorphisms of patients suffering from a rapidly progressing subtype of Alzheimer's dementia (rpAD).
Meissner, Bettina   +19 more
core   +1 more source

A Case of Sporadic Creutzfeldt-Jakob Disease Presenting as Conversion Disorder

open access: yesCase Reports in Psychiatry, 2017
Background. Creutzfeldt-Jakob disease is a rare disorder of the central nervous system. Its initial diagnosis may be obscured by its variable presentation.
Nikhil Yegya-Raman   +5 more
doaj   +1 more source

Public health concerns regarding sporadic Creutzfeldt–Jakob disease in China: a case series

open access: yesJournal of International Medical Research, 2019
In this study, we report three cases of sporadic Creutzfeldt–Jakob disease in China, two confirmed cases and one probable case. The aim of this study was to enrich the data regarding clinical and epidemiological features of this disease and to provide ...
Ru-Yi Zhou   +12 more
doaj   +1 more source

Tissue classification for the epidemiological assessment of surgical transmission of sporadic Creutzfeldt-Jakob disease. A proposal on hypothetical risk levels

open access: yesBMC Public Health, 2005
Background Epidemiological studies on the potential role of surgery in Creutzfeldt-Jakob Disease transmission have disclosed associations with history of specific surgical interventions or reported negative results.
Calero Miguel   +5 more
doaj   +1 more source

ENFERMEDAD DE JAKOB-CREUTZFELDT. A PROPÓSITO DE UN CASO

open access: yesRevistas Argentina de Medicina, 2017
La enfermedad de Jakob-Creutzfeuldt esporádica es la más común de las patologías priónicas humanas. Se presenta el caso de una paciente de 59 años de edad internada por trastornos conductuales cognitivos, acompañados de mioclonías y mutismo acinético.
Lucía González   +7 more
doaj   +2 more sources

Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the UK

open access: yes, 2006
To determine the frequency, in the UK, of sporadic Creutzfeldt-Jakob Disease (sCJD) with a cerebellar ataxic onset, and to describe the clinical features of the ...
Will, R G   +4 more
core   +1 more source

Prion diseases are efficiently transmitted by blood transfusion in sheep [PDF]

open access: yes, 2008
The emergence of variant Creutzfeld-Jakob disease, following on from the bovine spongiform encephalopathy (BSE) epidemic, led to concerns about the potential risk of iatrogenic transmission of disease by blood transfusion and the introduction of costly ...
Foster, J.   +8 more
core   +1 more source

Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Most suspected Creutzfeldt‐Jakob disease (CJD) cases are eventually diagnosed with other disorders. We assessed the utility of investigating Alzheimer's disease (AD) biomarkers and neurofilament light (NfL) in patients when CJD is suspected.
Zitianyu Wang   +12 more
doaj   +1 more source

Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3mP Score

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Early identification of patients with treatment‐responsive rapidly progressive dementia (RPD) is important as early treatment improves outcomes. The STAM3P score identifies treatment‐responsive RPD using “high risk” presenting features. We optimized performance by adding a time component (i.e., dementia within 3 months) and validated the ...
R. W. van Steenhoven   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy